Search
Segesterone acetate
go.drugbank.com/drugs/DB14583ApprovedSegesterone acetate is not an orally active compound, but it is proved to be a potent anti-ovulatory agent when given in implants, vaginal rings or percutaneous gel [A37090]. … On August 10, 2018, Annovera™ containing segesterone acetate and [ethinyl estradiol] was granted approval by the U.S.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: 16-Methylene-17-alpha-acetoxy-19-nor-4-pregnene-3,20-dione, 17-Hydroxy-16-methylene-19-norpregn-4-ene-3,20-dione acetateTocofersolan
go.drugbank.com/drugs/DB11635ApprovedCholestasis is the reduction or stoppage of bile flow, either to impaired secretion by _hepatocytes_ (liver cells) or obstruction [L2374], [L2375]. … It was approved by the European Medicines Agency (EMA) in June 2009 under the market name Vedrop.
Mixtures: Eye Health Areds 2 FormulaCategories: Compounds used in a research, industrial, or household setting, Vitamin ELamotrigine
go.drugbank.com/drugs/DB00555ApprovedInvestigationalLamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. … [A191350] Lamotrigine has relatively few side-effects and does not require laboratory monitoring.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazineDexamethasone
go.drugbank.com/drugs/DB01234ApprovedInvestigationalVet approvedDexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318] … Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic
Mixtures: TQ OFTAMOX D UD®, TQ OFTAMOX® D UDCategories: Corticosteroids, Moderately Potent (Group II), P-glycoprotein inducersTelisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigational[L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment … Telisotuzumab vedotin is an antibody-drug conjugate comprising [telisotuzumab], a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsEfbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigational[A33650,A262172] On November 22, 2023, efbemalenograstim alfa was approved by the FDA under the brand name Ryzneuta for the treatment of chemotherapy-induced neutropenia in adult patients with non-myeloid … This approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887]
Synonyms: Rh g-csf fc fusion protein f-627, Recombinant dimeric g-csf fusion protein f627Revefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigational[A40025] From the LAMA group, revefenacin is the first once-daily nebulized LAMA treatment.[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818] … Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA).
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesCertolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigational[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819] … [A176606] Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be
Products: CIMZIA 200 MG ILO IN FER, CIMZIA 200MG ILO IN FEROsilodrostat
go.drugbank.com/drugs/DB11837ApprovedInvestigational[L12123] It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013 … Osilodrostat is manufactured by Novartis under the brand name Isturisa.
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesSodium phosphate, monobasic
go.drugbank.com/drugs/DB09449ApprovedInvestigationalSodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.
Mixtures: K-Phos No. 2, UR N-C Urinary Antiseptic